[Morphofunctional state of the heart and activity of the kallikrein-kinin system in patients with chronic heart failure during treatment with captopril].
Coronary patients with heart failure (HF) stage I-III received captopril. The drug was found to attenuate symptoms of HF, to reduce the size of the left heart, to improve contractility. For stage HF I, kallikrein urinary excretion was similar to that of normal subjects, while in stage II-III patients it fell significantly. Captopril induced a drop in relevant secretion for stage I and a rise for stage II-III subjects. The drug administration did not influence the relations between the initial serum Na levels and kallikrein urinary excretion, nor it changed serum levels of Na and K. Alterations in morphofunctional characteristics of the heart and changes in diurnal urinary excretion of kallikrein demonstrated close relationships.